SAGILITY · NSE
SAGILITY LIMITED
₹45.66
+2.47% (+₹1.1)
Prev. close
₹44.56
Volume
1,74,50,697
Delivery %
40.9%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sagility for the short term, recommending a buy at ₹46.50 with a target of ₹54, and a stop loss at ₹42.” | Mehul KothariAnand Rathi | Sagility | PENDING | |
| “Bullish on Sagility for the next six months, recommending a buy between ₹43 and ₹44 with a target of ₹54 and a stop loss…” | Pabitro MukherjeeBajaj Broking | Sagility | PENDING |
Fundamentals
About SAGILITY LIMITED
Sagility Limited engages in the rendering voice and non-voice business process management and back-office transaction processing services in India, Jamaica, the Philippines, the United States, and Colombia. The company offers claims and membership managed services, such as digital mailroom, product and plan configuration, enrollment and billing, adjudication and adjustment, and appeals management solutions; engagement services; and payer clincal services. It also provides network operations suite comprising provider credentialing, provider data management, provider accuracy, and provider forward solutions; healthcare consulting services; sagility synchrony; healthcare payment integrity services; and provider services that includes patient access, clinical denials management, revenue cycle management, patient engagement, and coding solutions. In addition, the company offers member lifecycle management, provider lifecycle management, claims management, clinical utilization and care management, payment integrity, and provider revenue cycle management solutions. The company was formerly known as Sagility India Limited and changed its name to Sagility Limited in August 2025. Sagility Limited was incorporated in 2021 and is based in Bengaluru, India. The company operates as a subsidiary of Sagility B.V.
Details
Sector
Healthcare
Industry
Health Information Services
CEO
Mr. Ramesh Gopalan
Headquarters
Bengaluru
Employees
47,307
Website
sagility.comExchange
View on NSE ↗Key stats
Market cap
₹21,496.66 Cr
P/E ratio (TTM)
21.9
Dividend yield
0.44%
EPS (TTM)
₹2.10
Beta (1Y · daily vs NIFTY 50)
1.00
Shares float
231.19 Cr
EPS · quarter ended Jun 2026
₹0.46
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹4,218.41 Cr | ₹4,753.56 Cr | ₹5,569.92 Cr | ₹7,192.85 Cr | |
| EBITDA | ₹1,044.86 Cr | ₹1,116.04 Cr | ₹1,354.19 Cr | ₹1,825.43 Cr |
| ₹143.57 Cr | ₹228.27 Cr | ₹539.12 Cr | ₹924.77 Cr | |
| Diluted EPS | ₹0.31 | ₹0.49 | ₹1.17 | ₹1.98 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹10,590.48 Cr | ₹10,664.20 Cr | ₹11,050.66 Cr | ₹12,601.08 Cr | |
| ₹2,871.60 Cr | ₹2,531.71 Cr | ₹1,401.94 Cr | ₹1,110.54 Cr | |
| Stockholders' equity | ₹6,206.67 Cr | ₹6,443.13 Cr | ₹8,336.05 Cr | ₹9,659.10 Cr |
Inventory, CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹856.78 Cr | ₹973.26 Cr | ₹1,214.07 Cr | ₹1,202.97 Cr | |
| Investing cash flow | ₹-129.06 Cr | ₹-469.06 Cr | ₹-964.21 Cr | ₹-710.69 Cr |
| ₹-544.62 Cr | ₹-751.34 Cr | ₹-256.07 Cr | ₹-501.40 Cr | |
| Capital expenditure | ₹-143.68 Cr | ₹-182.73 Cr | ₹-124.44 Cr | ₹-192.21 Cr |
| End cash position | ₹585.29 Cr | ₹344.13 Cr | ₹343.76 Cr | ₹357.92 Cr |
Debt issued, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 24–Mar 25(3Q) | Jun 25–Sep 25(2Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|
| Promoter | 82.39% | 67.38% | 50.95% |
| Public | 17.61% | 32.62% | 49.05% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| SAGILITY LIMITED | ₹21,136.20 Cr | ₹45.02 | 21.1 | 2.19 | 9.6% | 0.11 | +29.1% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
23 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Ram Chaurasia Appointed Senior Director – Talent Acquisition at Sagility
Sagility appointed Ram Chaurasia as Senior Director – Talent Acquisition to strengthen its leadership in building and scaling its workforce. Chaurasia brings over 15 years of experience in talent acquisition and recruitment strategy. He previously held senior roles at WNS and Concentrix.